Healthcare / Medical Care FacilitiesNasdaqGS
$7.30
-0.29 (-3.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-3.1M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$991M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-12.9%
↓Gross Margin
18.0%
↓Debt/Equity
0.43
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+8.5%
FCF CAGR
-3.6%
FCF margin
3.1%
FCF / Net income
-0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $853.7M · net income $-30.3M · FCF $26.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $853.7M | $853.7M | $763.9M | $688.1M | $698.6M | $637.8M | $567.2M |
| Net Income | $-30.3M | $-30.3M | $-21.3M | $-40.7M | $-6.5M | $-44.0M | $26.3M |
| EBITDA | $-9.9M | $-9.9M | $1.2M | $-33.9M | $9.2M | $-43000.00 | $62.2M |
| EPS | — | — | -0.16 | -0.30 | -0.05 | -0.36 | 0.19 |
| Gross Margin | 18.0% | 18.0% | 17.3% | 14.7% | 19.4% | — | — |
| Operating Margin | -1.9% | -1.9% | -3.0% | -7.2% | -0.6% | -1.9% | 9.0% |
| Net Margin | -3.6% | -3.6% | -2.8% | -5.9% | -0.9% | -6.9% | 4.6% |
| Balance Sheet | |||||||
| Debt/Equity | 0.43 | 0.43 | 0.42 | 0.37 | 0.26 | 0.21 | 2.08 |
| Current Ratio | 1.03 | 1.03 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $26.6M | $26.6M | $-44.8M | $-3.1M | $-10.9M | $-25.1M | $32.0M |
| Returns | |||||||
| ROE | -12.9% | -12.9% | -7.9% | -13.7% | -2.0% | -13.1% | 26.0% |
| Valuation | |||||||
| EV/EBITDA | — | — | 649.21 | — | 54.65 | — | — |
| P/B | 4.21 | 4.21 | 2.57 | 3.06 | 1.81 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 11.8% | 11.8% | 11.0% | -1.5% | — | 12.4% | — |
| EPS Growth | — | — | 46.7% | -500.0% | — | -289.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+78.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → n/d
Residual
+78.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.